Literature DB >> 16272354

Proliferation response of leukemic cells to CD70 ligation oscillates with recurrent remission and relapse in a low-grade lymphoma.

Yael Kaufmann1, Ninette Amariglio, Esther Rosenthal, Yasmine Jacob Hirsch, Amira Many, Gideon Rechavi.   

Abstract

Interactions of the TNF-related cell surface ligand CD70 with its receptor CD27 provide a costimulatory signal in B and T cell activation. Functional CD70-CD27 interactions could contribute to lymphoma and leukemia progression. This possibility was studied using DNA microarrays on a unique case of low-grade lymphoma/leukemia characterized by recurrent cycles of acute leukemic phase alternating with spontaneous remission. Upon induction of the acute phase expression of CD70 and CD27 in the leukemic cells increased 38- and 25-fold, respectively. Coexpression of membrane CD70 and CD27 on the leukemic (CD5+CD19+) cells was maximal 2-3 days following initiation of the attack. Soluble CD27 in the patient's serum was elevated during remission and further increased in the attack. Functional tests showed that neither anti-CD70 nor anti-CD27 Abs affect the rate of apoptosis. However, the anti-CD70 Ab specifically enhanced proliferation of the remission phase leukemic cells, whereas proliferation of the acute-phase counterparts that express higher level of membrane CD70 was unaffected. Hence, in this lymphoma/leukemia, membrane CD70 is presented on the leukemic cells in a responsive state during the remission and a nonresponsive state during the attack. Presumably, CD70 in its responsive state provides a costimulatory receptor for initiating the next acute phase while its nonresponsive state enables the remission.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16272354     DOI: 10.4049/jimmunol.175.10.6940

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  Stroma-dependent apoptosis in clonal hematopoietic precursors correlates with expression of PYCARD.

Authors:  Andrew J Mhyre; A Mario Marcondes; Emily Y Spaulding; H Joachim Deeg
Journal:  Blood       Date:  2008-10-22       Impact factor: 22.113

Review 2.  The CD70-CD27 axis in oncology: the new kids on the block.

Authors:  Tal Flieswasser; Astrid Van den Eynde; Jonas Van Audenaerde; Jorrit De Waele; Filip Lardon; Carsten Riether; Hans de Haard; Evelien Smits; Patrick Pauwels; Julie Jacobs
Journal:  J Exp Clin Cancer Res       Date:  2022-01-06

3.  Can we negotiate with a tumor?

Authors:  Claire M Wolfrom; Michel Laurent; Jean Deschatrette
Journal:  PLoS One       Date:  2014-08-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.